Thus, a phase two trial (NCT02572453) including Onalespib/AT-13387 (Astex Therapeutics), a HSP90 inhibitor, is ongoing in patients with relapses/refractory ALK(+) ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.